CureLab Oncology, a clinical-stage biotech company, announced on Thursday that it has named Dr Aubrey C Galloway as its new chief medical officer (CMO).
In the new role, Dr Galloway will manage the clinical development strategy for the company's lead investigational compound, Elenagen, and new forms of treatment that CureLab is presently developing.
Dr Galloway is a cardiac surgeon and the Seymour Cohn Professor of Cardiothoracic Surgery at NYU Langone Health. He has directed the department's Cardiac Surgery Research and Clinical Trials program for more than 20 years and worked as Chair of the Department of Cardiothoracic Surgery for 15 years.
Renibus Therapeutics completes RBT-1 Phase 3 clinical trial enrolment
Rona Therapeutics granted Chinese approval of IND application for hypertension drug candidate RN1871
Clario partners with AWS on advancing clinical data analysis with generative AI
Langhua Pharmaceutical passes US FDA's on-site inspection
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Ionis announces partnership expansion with Sobi for global olezarsen commercialisation
BioCardia secures Japanese patent for Helix biotherapeutic delivery system
Doer Bio completes DR10624phase two clinical study enrolment
Kancera and Recardio sign letter of intent for licensing agreement
Novo Nordisk launches NovoCare Pharmacy to reduce Wegovy costs and expand access
Redx Pharma reports positive Phase 1 results for RXC008 in fibrostenotic Crohn's disease
Hims & Hers acquires Trybe Labs to expand at-home testing capabilities
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline